Breast Cancer: Clinical Trials

Showing 1 - 50 of 61 trials
Title Investigator
A Long-Term Study of Sexual and Reproductive Health in Women with Breast Cancer and Lymphoma
[Protocol 12-249]
Goldfarb, Shari, MD
A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
[Protocol 12-267]
Hudis, Clifford, MD
A Phase I Study of ARN-810 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
[Protocol 13-049]
Dickler, Maura, MD
A Phase I Study of BKM120 and Olaparib in Patients with High-Grade Serous Ovarian Cancer
[Protocol 12-233]
Bell-McGuinn, Katherine, MD, PhD
A Phase I Study of BYL719 with Letrozole or Exemestane for Treating Locally Advanced Inoperable or Metastatic Breast Cancer
[Protocol 13-027]
Dickler, Maura, MD
A Phase I Study of CB-839 in Patients with Advanced Solid Tumors
[Protocol 14-111]
Harding, James, MD
A Phase I Study of Debio1347 in Patients with Advanced Cancers Containing FGFR Alterations
[Protocol 13-131]
Voss, Martin, MD
A Phase I Study of DLYE5953A in Patients with Advanced or Persistent Solid Tumors
[Protocol 14-089]
Modi, Shanu, MD
A Phase I Study of Enzalutamide (MDV3100) in Patients with Previously Treated Metastatic Breast Cancer
[Protocol 12-155]
Traina, Tiffany, MD
A Phase I Study of Ganetespib with Paclitaxel and Trastuzumab in Women with Metastatic Breast Cancer
[Protocol 13-168]
Modi, Shanu, MD
A Phase I Study of GL-ONC1 for Treating Malignant Pleural Effusion
[Protocol 12-169]
Rusch, Valerie, MD
A Phase I Study of LJM716, BYL719, and Trastuzumab in Women with Metastatic HER2-Positive Breast Cancer
[Protocol 14-057]
Modi, Shanu, MD
A Phase I Study of Lurbinectedin plus Paclitaxel in Patients with Advanced Solid Tumors
[Protocol 13-170]
Drilon, Alexander, MD
A Phase I Study of SGN-LIV1A in Women with Metastatic Breast Cancer
[Protocol 14-013]
Modi, Shanu, MD
A Phase I Study of Topical Calcitriol (Compound 31543) to Prevent Hair Loss in Women Receiving Paclitaxel for Advanced Breast Cancer
[Protocol 11-205]
Lacouture, Mario, MD
A Phase I Study of Whole Brain Radiation Therapy plus Sorafenib for Patients with Breast Cancer Brain Metastases
[Protocol 12-046]
Seidman, Andrew, MD
A Phase I/II Clinical Trial of Temsirolimus plus Neratinib for Subjects with Metastatic HER2-Amplified or Triple-Negative Breast Cancer
[Protocol 10-005]
Chandarlapaty, Sarat, MD, PhD
A Phase I/II Study of Intrathecal Trastuzumab in Women with HER2-Positive Breast Cancer that Spread to the Spinal Fluid
[Protocol 12-123]
Pentsova, Elena, MD
A Phase I/II Study of Nivolumab Alone and with Ipilimumab in Patients with Advanced or Metastatic Solid Tumors
Relapsed/Refractory
[Protocol 13-187]
Callahan, Margaret, MD, PhD
A Phase IA/IB Study of RO5509554 Alone and with Paclitaxel in Patients with Advanced Solid Tumors
[Protocol 14-086]
D'Angelo, Sandra, MD
A Phase IB Study of LEE011 and Exemestane with and without Everolimus in Women with Locally Advanced or Metastatic Breast Cancer
[Protocol 13-179]
Modi, Shanu, MD
A Phase IB Study of LY2835219 plus Hormonal Therapy in Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
[Protocol 14-085]
Dickler, Maura, MD
A Phase Ib Study of Oral BGJ398 and BYL719 in Patients with Certain Advanced Solid Tumors
[Protocol 13-246]
Fury, Matthew, MD, PhD
A Phase II Study of BYL719 plus AMG 479 (Ganitumab) in Patients with Advanced Ovarian Cancer or Hormone Receptor-Positive Breast Cancer
[Protocol 13-251]
Modi, Shanu, MD
A Phase II Study of Cabozantinib in Women with Hormone Receptor-Positive Breast Cancer that Spread to the Bone
[Protocol 12-091]
Fornier, Monica, MD
A Phase II Study of Capecitabine with Lapatinib or Neratinib in Patients with Metastatic HER2-Positive Breast Cancer
[Protocol 13-121]
Latif, Asma, MD
A Phase II Study of Dose-Dense Doxorubicin and Cyclophosphamide followed by Eribulin Mesylate for the Adjuvant Treatment of Early-Stage Breast Cancer
[Protocol 10-190]
Traina, Tiffany, MD
A Phase II Study of Exemestane with and without Enzalutamide in Women with Advanced Hormone Receptor-Positive Breast Cancer
[Protocol 13-257]
Traina, Tiffany, MD
A Phase II Study of LY2835219 in Patients with Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
[Protocol 14-143]
Dickler, Maura, MD
A Phase II Study of Multi-Beam Intensity-Modulated Radiation Therapy for Patients with Locally Advanced Breast Cancer Who Had Implant Reconstruction
[Protocol 14-028]
Ho, Alice, MD
A Phase II Study of Neratinib to Treat Metastatic Breast Cancer that Does Not Overexpress HER2 but Has a HER2 Mutation
[Protocol 13-195]
Modi, Shanu, MD
A Phase II Study of SNX-5422 in Patients with Select Advanced HER2 Cancers
[Protocol 13-112]
Voss, Martin, MD
A Phase II Study of Veliparib plus Temozolomide, Veliparib plus Carboplatin and Paclitaxel, or Carboplatin and Paclitaxel with Placebo in Patients with BRCA Mutations and Metastatic Breast Cancer
[Protocol 12-122]
Robson, Mark, MD
A Phase II Study to See if Carvedilol Can Help Prevent Heart Function Problems in Women Receiving Anthracyclines or Anti-HER2 Therapies for Breast Cancer
[Protocol 14-099]
Yu, Anthony, MD
A Phase III Study Comparing Mometasone Furoate with Eucerin to Treat Radiation-Related Skin Redness and Peeling in Breast Cancer Patients after Mastectomy
[Protocol 13-069]
Olm-Shipman, Molly, RN
A Phase III Study Comparing Two Different HER2-Targeting Chemotherapy Regimens in Patients with Early-Stage HER2-Positive Breast Cancer
[Protocol 14-045]
Dang, Chau, MD
A Phase III Study Evaluating of the Role of Axillary (Armpit) Lymph Node Removal in Patients with Breast Cancer with Positive Sentinel Lymph Nodes after Preoperative Chemotherapy
Newly Diagnosed
[Protocol 14-151]
King, Tari, MD
A Phase III Study of Hormone Therapy with and without Chemotherapy in Patients with HER2-Negative Breast Cancer and 1-3 Positive Lymph Nodes and a Recurrence Score of 25 or Less
[Protocol 12-118]
Lake, Diana, MD
A Phase III Study of Olaparib versus Standard Chemotherapy to Treat Patients with Metastatic Breast Cancer Who Have BRCA Mutations
[Protocol 14-157]
Robson, Mark, MD
A Phase III Study of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
[Protocol 11-190]
King, Tari, MD
A Pilot Study of a Geriatric-Specific Psychoeducational Intervention for Elderly Cancer Patients
[Protocol 09-116]
Roth, Andrew, MD
A Study Assessing the Influence of Breast MRI Before Lumpectomy on Outcomes, Quality of Life, and Costs in Women with Breast Cancer
Newly Diagnosed
[Protocol 14-198]
King, Tari, MD
A Study Assessing the Safety and Tolerability of Supervised Aerobic Exercise Training in Women with Metastatic Breast Cancer
[Protocol 14-170]
Jones, Lee, PhD
A Study Assessing the Use of Dual Handset Phones to Improve Communication with Inpatients Who Have Limited English Proficiency
[Protocol 14-042]
Kumar, Chhavi, MD
A Study Comparing Whole Breast Screening Ultrasound with 3D Mammography (Digital Breast Tomosynthesis) in Women Scheduled for Digital Mammography and Ultrasound
Newly Diagnosed & Relapsed/Refractory
[Protocol 14-119]
Sung, Janice, MD
A Study of Non-Hormonal Vaginal Moisturizer in Hormone Receptor-Positive Postmenopausal Cancer Survivors
[Protocol 12-232]
Carter, Jeanne, PhD
Acupuncture for Chronic Lymphedema After Breast Cancer Treatment
[Protocol 12-210]
Cassileth, Barrie, PhD
Assessment of a Customized Computer Program for Reducing Fears of Breast Cancer Recurrence
[Protocol 11-204]
Lichtenthal, Wendy, PhD
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
[Protocol 12-089]
Tew, William, MD
Clinical Significance of Germline BRCA Mutations
[Protocol 96-051]
Offit, Kenneth, MD